Risk factors for Clostridioides (Clostridium) difficile infection following solid organ transplantation in children

Elisa Ochfeld*, Lauren Christine Balmert, Sameer J Patel, William J Muller, Larry Kenneth Kociolek

*Corresponding author for this work

Research output: Contribution to journalArticle

Abstract

Background: Clostridioides (Clostridium) difficile infection (CDI) in pediatric solid organ transplant (SOT) recipients is a growing problem, though CDI risk factors in this population are poorly understood. Our objective was to characterize CDI risk factors in pediatric SOT recipients. Methods: This retrospective case-control study, performed at a single freestanding academic children's hospital, included all SOT recipients age 1-22 years who were tested for C. difficile by toxin B gene PCR between August 2009 and August 2017. CDI risk factors were assessed by comparing PCR-positive and PCR-negative cases by generalized linear mixed models. Results: Between August 2009 and August 2017, 409 SOTs were performed of which 138 (33.7%), 134 (32.8%), 131 (32.0%), and 6 (1.5%) were kidney, liver, heart, and small intestine transplants, respectively. Of 205 SOT recipients were tested for CDI, with 723 C. difficile PCR tests performed among these patients. 68/205 (33%) patients developed CDI at least once during the study period. Median (interquartile range) time to diagnosis of first CDI following SOT was 8.9 (1.2, 19.6) months. CDI was independently associated with calcineurin inhibitor use at time of C. difficile testing (odds ratio [OR] 2.38, 95% confidence interval [CI] 1.08, 5.24, P = 0.03) and systemic antibiotic exposure within 30 days of C. difficile testing (OR 1.74, 95% CI 1.08, 2.79, P = 0.02). Conclusions: CDI is a common, relatively late post-transplant complication and independently associated with calcineurin inhibitor and systemic antibiotic exposure. The potential impact of specific immunosuppressive drug and antibiotic selection on CDI risk reduction requires further investigation.

Original languageEnglish (US)
Article numbere13149
JournalTransplant Infectious Disease
DOIs
StatePublished - Jan 1 2019

Fingerprint

Clostridium Infections
Clostridium difficile
Organ Transplantation
Transplants
Polymerase Chain Reaction
Anti-Bacterial Agents
Odds Ratio
Confidence Intervals
Pediatrics
Risk Reduction Behavior
Immunosuppressive Agents
Small Intestine
Case-Control Studies
Linear Models

Keywords

  • Clostridioides difficile
  • Clostridium difficile
  • immunosuppression
  • pediatrics
  • solid organ transplantation

ASJC Scopus subject areas

  • Transplantation
  • Infectious Diseases

Cite this

@article{6a6ce664ef6544d290dcc89cc0d2519c,
title = "Risk factors for Clostridioides (Clostridium) difficile infection following solid organ transplantation in children",
abstract = "Background: Clostridioides (Clostridium) difficile infection (CDI) in pediatric solid organ transplant (SOT) recipients is a growing problem, though CDI risk factors in this population are poorly understood. Our objective was to characterize CDI risk factors in pediatric SOT recipients. Methods: This retrospective case-control study, performed at a single freestanding academic children's hospital, included all SOT recipients age 1-22 years who were tested for C. difficile by toxin B gene PCR between August 2009 and August 2017. CDI risk factors were assessed by comparing PCR-positive and PCR-negative cases by generalized linear mixed models. Results: Between August 2009 and August 2017, 409 SOTs were performed of which 138 (33.7{\%}), 134 (32.8{\%}), 131 (32.0{\%}), and 6 (1.5{\%}) were kidney, liver, heart, and small intestine transplants, respectively. Of 205 SOT recipients were tested for CDI, with 723 C. difficile PCR tests performed among these patients. 68/205 (33{\%}) patients developed CDI at least once during the study period. Median (interquartile range) time to diagnosis of first CDI following SOT was 8.9 (1.2, 19.6) months. CDI was independently associated with calcineurin inhibitor use at time of C. difficile testing (odds ratio [OR] 2.38, 95{\%} confidence interval [CI] 1.08, 5.24, P = 0.03) and systemic antibiotic exposure within 30 days of C. difficile testing (OR 1.74, 95{\%} CI 1.08, 2.79, P = 0.02). Conclusions: CDI is a common, relatively late post-transplant complication and independently associated with calcineurin inhibitor and systemic antibiotic exposure. The potential impact of specific immunosuppressive drug and antibiotic selection on CDI risk reduction requires further investigation.",
keywords = "Clostridioides difficile, Clostridium difficile, immunosuppression, pediatrics, solid organ transplantation",
author = "Elisa Ochfeld and Balmert, {Lauren Christine} and Patel, {Sameer J} and Muller, {William J} and Kociolek, {Larry Kenneth}",
year = "2019",
month = "1",
day = "1",
doi = "10.1111/tid.13149",
language = "English (US)",
journal = "Transplant Infectious Disease",
issn = "1398-2273",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Risk factors for Clostridioides (Clostridium) difficile infection following solid organ transplantation in children

AU - Ochfeld, Elisa

AU - Balmert, Lauren Christine

AU - Patel, Sameer J

AU - Muller, William J

AU - Kociolek, Larry Kenneth

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background: Clostridioides (Clostridium) difficile infection (CDI) in pediatric solid organ transplant (SOT) recipients is a growing problem, though CDI risk factors in this population are poorly understood. Our objective was to characterize CDI risk factors in pediatric SOT recipients. Methods: This retrospective case-control study, performed at a single freestanding academic children's hospital, included all SOT recipients age 1-22 years who were tested for C. difficile by toxin B gene PCR between August 2009 and August 2017. CDI risk factors were assessed by comparing PCR-positive and PCR-negative cases by generalized linear mixed models. Results: Between August 2009 and August 2017, 409 SOTs were performed of which 138 (33.7%), 134 (32.8%), 131 (32.0%), and 6 (1.5%) were kidney, liver, heart, and small intestine transplants, respectively. Of 205 SOT recipients were tested for CDI, with 723 C. difficile PCR tests performed among these patients. 68/205 (33%) patients developed CDI at least once during the study period. Median (interquartile range) time to diagnosis of first CDI following SOT was 8.9 (1.2, 19.6) months. CDI was independently associated with calcineurin inhibitor use at time of C. difficile testing (odds ratio [OR] 2.38, 95% confidence interval [CI] 1.08, 5.24, P = 0.03) and systemic antibiotic exposure within 30 days of C. difficile testing (OR 1.74, 95% CI 1.08, 2.79, P = 0.02). Conclusions: CDI is a common, relatively late post-transplant complication and independently associated with calcineurin inhibitor and systemic antibiotic exposure. The potential impact of specific immunosuppressive drug and antibiotic selection on CDI risk reduction requires further investigation.

AB - Background: Clostridioides (Clostridium) difficile infection (CDI) in pediatric solid organ transplant (SOT) recipients is a growing problem, though CDI risk factors in this population are poorly understood. Our objective was to characterize CDI risk factors in pediatric SOT recipients. Methods: This retrospective case-control study, performed at a single freestanding academic children's hospital, included all SOT recipients age 1-22 years who were tested for C. difficile by toxin B gene PCR between August 2009 and August 2017. CDI risk factors were assessed by comparing PCR-positive and PCR-negative cases by generalized linear mixed models. Results: Between August 2009 and August 2017, 409 SOTs were performed of which 138 (33.7%), 134 (32.8%), 131 (32.0%), and 6 (1.5%) were kidney, liver, heart, and small intestine transplants, respectively. Of 205 SOT recipients were tested for CDI, with 723 C. difficile PCR tests performed among these patients. 68/205 (33%) patients developed CDI at least once during the study period. Median (interquartile range) time to diagnosis of first CDI following SOT was 8.9 (1.2, 19.6) months. CDI was independently associated with calcineurin inhibitor use at time of C. difficile testing (odds ratio [OR] 2.38, 95% confidence interval [CI] 1.08, 5.24, P = 0.03) and systemic antibiotic exposure within 30 days of C. difficile testing (OR 1.74, 95% CI 1.08, 2.79, P = 0.02). Conclusions: CDI is a common, relatively late post-transplant complication and independently associated with calcineurin inhibitor and systemic antibiotic exposure. The potential impact of specific immunosuppressive drug and antibiotic selection on CDI risk reduction requires further investigation.

KW - Clostridioides difficile

KW - Clostridium difficile

KW - immunosuppression

KW - pediatrics

KW - solid organ transplantation

UR - http://www.scopus.com/inward/record.url?scp=85070443317&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070443317&partnerID=8YFLogxK

U2 - 10.1111/tid.13149

DO - 10.1111/tid.13149

M3 - Article

JO - Transplant Infectious Disease

JF - Transplant Infectious Disease

SN - 1398-2273

M1 - e13149

ER -